RAF1 - Raf-1 proto-oncogene, serine/threonine kinase Gene
Species: Macaca fascicularis
Gene Type: protein coding
Gene ID: 102125312
About RAF1
Primary_assembly 2: 142,304,678-142,386,051 reverse strand.Macaca_fascicularis_6.0:CM021940.1
This gene has 2 transcripts (splice variants), 218 orthologues and 22 paralogues.
RAF1 Products (7)
| mRNA | Protein | Name |
|---|---|---|
| XM_045385722.1 | XP_045241657.1 | RAF proto-oncogene serine/threonine-protein kinase isoform X1 |
| XM_045385723.1 | XP_045241658.1 | RAF proto-oncogene serine/threonine-protein kinase isoform X1 |
| XM_045385728.1 | XP_045241663.1 | RAF proto-oncogene serine/threonine-protein kinase isoform X4 |
| XM_045385725.1 | XP_045241660.1 | RAF proto-oncogene serine/threonine-protein kinase isoform X1 |
| XM_045385727.1 | XP_045241662.1 | RAF proto-oncogene serine/threonine-protein kinase isoform X3 |
| XM_045385724.1 | XP_045241659.1 | RAF proto-oncogene serine/threonine-protein kinase isoform X1 |
| XM_045385726.1 | XP_045241661.1 | RAF proto-oncogene serine/threonine-protein kinase isoform X2 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
RAF proto-oncogene serine/threonine-protein kinase |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-12057 | Vemurafenib | 99.90% | Yes | |
| HY-10331 | Regorafenib | 99.93% | Yes | |
| HY-10201S | Sorafenib-d3 | 99.57% | Unkown | |
| HY-10331A | Regorafenib monohydrate | 99.94% | Yes | |
| HY-N6670 | Cefotetan | 99.75% | Unkown | |
| HY-13308 | Regorafenib Hydrochloride | 99.58% | Yes | |
| HY-10201R | Sorafenib (Standard) | 99.71% | Unkown | |
| HY-10331B | Regorafenib mesylate | / | Unkown | |
| HY-10201AR | Sorafenib tosylate (Standard) | / | Unkown |
Clinical Phase
Bioactive Molecules
(6)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-159127 | HRS-4642 | 98.38% | Phase 2 | |
| HY-114491 | Rineterkib | Inhibitor | 98.79% | Phase 2 |
| HY-114491A | Rineterkib hydrochloride | Inhibitor | 99.81% | Phase 2 |
| HY-134813 | MRTX1133 | Inhibitor | 99.97% | Phase 1 |
| HY-51424 | PLX-4720 | Inhibitor | 99.90% | Phase 1 |
| HY-158107 | BBO-8520 | Inhibitor | 99.90% | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(44)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-11004 | AZ 628 | 99.44% | Unkown | |
| HY-18832 | AWL-II-38.3 | Inhibitor | 99.68% | Unkown |
| HY-I0678 | Regorafénib N-oxyde (M2) | 98.15% | Unkown | |
| HY-W013411A | Locostatin | 99.88% | Unkown | |
| HY-122914 | KRAS inhibitor-3 | Inhibitor | 99.87% | Unkown |
| HY-P1039A | R18 TFA | 99.36% | Unkown | |
| HY-112440 | HZX-02-059 | Inhibitor | 99.40% | Unkown |
| HY-123673 | MCP110 | Inhibitor | 99.82% | Unkown |
| HY-15716 | Kobe0065 | 99.93% | Unkown | |
| HY-115501 | (E)-FOBISIN101 | Inhibitor | 95.63% | Unkown |
| HY-117737A | RRD-251 | 99.87% | Unkown | |
| HY-15717 | Kobe2602 | Inhibitor | 98.20% | Unkown |
| HY-181420A | BBO-11818 | 99.77% | Unkown | |
| HY-10201S2 | Sorafenib-13C,d3 | 98.35% | Unkown | |
| HY-177511 | KRAS G12D-IN-30 | Inhibitor | 99.38% | Unkown |
| HY-164365 | PROTAC K-Ras Degrader-2 | Degrader | / | Unkown |
| HY-134813A | MRTX1133 formic | Inhibitor | 98.23% | Unkown |
| HY-158107A | (4R)-BBO-8520 | Inhibitor | / | Unkown |
| HY-P1039 | R18 | / | Unkown | |
| HY-W013411 | (E/Z)-Locostatin | Control | 99.52% | Unkown |
| HY-10201S1 | Sorafenib-d4 | 99.9% | Unkown | |
| HY-10201S4 | Sorafenib-d3 tosylate | Inhibitor | / | Unkown |
| HY-10331S1 | Regorafenib-13C,d3 | / | Unkown | |
| HY-12057S | Vemurafenib-d5 | / | Unkown | |
| HY-12057S1 | Vemurafenib-d7 | / | Unkown | |
| HY-161760 | Ferroptosis inducer-3 | Inhibitor | / | Unkown |
| HY-175870A | (7R)-Eras-4001 | Inhibitor | / | Unkown |
| HY-179133 | HDB-1 | Inhibitor | 98.02% | Unkown |
| HY-181420 | (S,R,S)-BBO-11818 | / | Unkown | |
| HY-182749 | KRAS-IN-58 | Inhibitor | / | Unkown |
| HY-183674 | MEK-IN-10 | / | Unkown | |
| HY-E70747 | MEK5 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-E70765 | RAF1 YDYD Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-I0678S | Regorafénib N-oxyde-d3 (M2) | / | Unkown | |
| HY-I0678S1 | Regorafénib N-oxyde (M2)-13C,d3 | / | Unkown | |
| HY-N13009 | MO-2097 | / | Unkown | |
| HY-RS11619 | RAF1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS11620 | Raf1 Mouse Pre-designed siRNA Set A | / | Unkown | |
| HY-RS11621 | Raf1 Rat Pre-designed siRNA Set A | / | Unkown | |
| HY-RS12020 | RNASE3 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W1126467 | RAS-IN-5 | Inhibitor | / | Unkown |
| HY-51424S | PLX-4720-d7 | Inhibitor | / | Unkown |
| HY-N15264 | Azaspirene | Inhibitor | / | Unkown |
| HY-RS26697 | Rnase2 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service